Company Filing History:
Years Active: 2008
Title: Christopher J Phiel: Innovator in Alzheimer's Disease Treatment
Introduction
Christopher J Phiel is a notable inventor based in Royersford, PA (US). He has made significant contributions to the field of Alzheimer's disease research through his innovative patent. His work focuses on the regulation of glycogen synthase kinase-3 (GSK-3) activity, which is crucial in the treatment and prevention of this debilitating condition.
Latest Patents
Phiel holds a patent for the "Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease." This patent presents a novel use of therapeutic concentrations of GSK-3 inhibitors, including lithium, to block or reduce the processing of amyloid precursor proteins into beta-amyloid peptides. These peptides are believed to be the principal cause of Alzheimer's disease. The methods outlined in the patent provide a pathway for the prevention, inhibition, or potential reversal of the disease. Additionally, the patent includes methods for using agents that specifically target the α isoform of GSK-3, making these selective inhibitors particularly useful in treatment strategies.
Career Highlights
Christopher J Phiel is affiliated with the University of Pennsylvania, where he continues to advance research in the field of neurodegenerative diseases. His work has garnered attention for its potential impact on Alzheimer's treatment and prevention.
Collaborations
Phiel has collaborated with notable colleagues, including Christina A Wilson and Virginia Man-Yee Lee, contributing to a rich environment of innovation and research.
Conclusion
Christopher J Phiel's contributions to Alzheimer's disease research through his patent on GSK-3 inhibitors highlight his role as an important inventor in the field. His work not only aims to advance treatment options but also offers hope for those affected by this challenging disease.